Clinical trial
Alemtuzumab in Treating Patients With Advanced Chronic Lymphocytic Leukemia That…
NCT00274976 · German CLL Study Group, Other · Completed
Key facts
| NCT number | NCT00274976 |
|---|---|
| Title | Alemtuzumab in Treating Patients With Advanced Chronic Lymphocytic Leukemia That Did Not Respond to Previous Fludarabine |
| Official title | Subcutaneous Campath-1H in Fludarabine-Refractory CLL |
| Lead sponsor | German CLL Study Group, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological |
| Interventions | alemtuzumab |
| Start date | Sep 1, 2002 |
| Completion | Aug 1, 2009 |
| First posted | Jan 11, 2006 |
| Last update posted | Nov 6, 2013 |
| Countries | Austria, Germany |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: